General Oncology Announces Promising Preliminary Phase 1 Results from SHARON Trial Presented at ESMO 2025

The SHARON trial is ongoing and will be expanding to include patients without a BRCA or PALB2 mutation, and General Oncology plans to continue evaluating outcomes and long-term follow-up in this ...

Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia

Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopeniaRecommendation based on LUNA 3 phase 3 study ...

Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Mo…

ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson’s disease – – ARV-102 ...

MaaT Pharma Announces Positive Second Safety Interim Analysis from DSMB for Phase 2b PHOEBUS Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

MaaT Pharma Announces Positive Second Safety Interim Analysis from DSMB for Phase 2b PHOEBUS Trial Evaluating MaaT033 for ...
Business Wire

Enrollment Initiated for Phase 2 Clinical trial in Early Alzheimer’s with Sinaptica’s Second-Generation Precision Neuromodulation System

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s and ...
ascopubs.org

A phase II, single-arm, open-label clinical trial to evaluate the combination of cadonilimab injection and gut microbiota modulation in the treatment of persistent, recurrent ...

ANA trial: Development of a diagnostic test and dynamic evaluation of ctDNA to optimize follow-up and tailor treatment in patients with HPV-related cervical and anal tumors. Background: Current ...